Literature DB >> 1655340

Effects of continuous infusion of atrial natriuretic peptide on the pulmonary hypertension induced by chronic hypoxia in rats.

L Zhao1, R J Winter, T Krausz, J M Hughes.   

Abstract

1. The effects of the continuous infusion of atrial natriuretic peptide on the development of pulmonary hypertension were studied in rats exposed to chronic hypoxia. 2. Continuous intravenous infusion of two doses of synthetic rat atrial natriuretic peptide, 300 ng/h per rat (0.10 pmol/h per rat) and 800 ng/h per rat (0.28 pmol/h per rat), attenuated the development of pulmonary hypertension in rats exposed to chronic hypoxia (fractional concentration of oxygen in inspired air = 10%) for 7 days: (i) the pulmonary artery pressure (mean +/- SD) in the vehicle-treated hypoxic group was 45 +/- 6 mmHg compared with 28 +/- 6 mmHg in the vehicle-treated normotoxic group (n = 8, P less than 0.001); (ii) treatment with atrial natriuretic peptide in normoxia did not alter the pulmonary artery pressure, systemic blood pressure or heart rate; (iii) treatment with atrial natriuretic peptide in hypoxia resulted in a lower pulmonary artery pressure in the group treated with 800 ng of atrial natriuretic peptide/h per rat (38 +/- 8 mmHg, P less than 0.05 compared with the vehicle-treated hypoxic group) without affecting the systemic blood pressure or heart rate. 3. Chronic hypoxia resulted in an extension of vascular smooth muscle towards the periphery of the lung with the development of muscle in normally non-muscularized vessels (remodelling).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1655340     DOI: 10.1042/cs0810379

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  9 in total

Review 1.  Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies.

Authors:  Stephen L Archer; E Kenneth Weir; Martin R Wilkins
Journal:  Circulation       Date:  2010-05-11       Impact factor: 29.690

2.  Angiotensin II receptor expression and inhibition in the chronically hypoxic rat lung.

Authors:  L Zhao; R al-Tubuly; A Sebkhi; A A Owji; D J Nunez; M R Wilkins
Journal:  Br J Pharmacol       Date:  1996-11       Impact factor: 8.739

3.  The effects of chronic hypoxia on renal function in the rat.

Authors:  M Neylon; J M Marshall; E J Johns
Journal:  J Physiol       Date:  1997-05-15       Impact factor: 5.182

4.  Acute effects of ANP and BNP on hypoxic pulmonary vasoconstriction in humans.

Authors:  R I Cargill; B J Lipworth
Journal:  Br J Clin Pharmacol       Date:  1995-12       Impact factor: 4.335

Review 5.  The role of the renin-angiotensin and natriuretic peptide systems in the pulmonary vasculature.

Authors:  R I Cargill; B J Lipworth
Journal:  Br J Clin Pharmacol       Date:  1995-07       Impact factor: 4.335

6.  Neutral endopeptidase (NEP) inhibition in rats with established pulmonary hypertension secondary to chronic hypoxia.

Authors:  J S Thompson; W Sheedy; A H Morice
Journal:  Br J Pharmacol       Date:  1994-12       Impact factor: 8.739

Review 7.  Rodent models of cardiopulmonary disease: their potential applicability in studies of air pollutant susceptibility.

Authors:  U P Kodavanti; D L Costa; P A Bromberg
Journal:  Environ Health Perspect       Date:  1998-02       Impact factor: 9.031

Review 8.  Biochemical and Clinical Impact of Organic Uremic Retention Solutes: A Comprehensive Update.

Authors:  Raymond Vanholder; Anneleen Pletinck; Eva Schepers; Griet Glorieux
Journal:  Toxins (Basel)       Date:  2018-01-08       Impact factor: 4.546

9.  Endothelial actions of atrial natriuretic peptide prevent pulmonary hypertension in mice.

Authors:  Franziska Werner; Baktybek Kojonazarov; Birgit Gaßner; Marco Abeßer; Kai Schuh; Katharina Völker; Hideo A Baba; Bhola K Dahal; Ralph T Schermuly; Michaela Kuhn
Journal:  Basic Res Cardiol       Date:  2016-02-24       Impact factor: 17.165

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.